Business Model

Three revenue streams. One aging platform.

EXHLS generates recurring revenue across three orthogonal channels: direct-to-consumer longevity memberships, enterprise licensing to health systems and insurers, and longitudinal research data partnerships with pharmaceutical and biotech firms.

Each channel is structurally independent — a downturn in consumer discretionary spending does not affect enterprise contract revenue. The model is designed for resilience, not just growth.

Explore revenue architecture →

Market opportunity

The numbers behind the thesis.

Global longevity market size by 2030Preventive health · Diagnostics · Wearables

$610B

Annual revenue per enterprise health system contractMulti-year licensing · Implementation · Support

$2.4M

Consumer membership annual recurring revenue per memberQuarterly assessment · Continuous monitoring · Protocol

$4,800

Research data partnership value per longitudinal cohortDe-identified · Multi-year · Pharmaceutical-grade

$12M

Revenue architecture

Three channels. Recurring revenue.

Each revenue channel is structurally independent — consumer membership, enterprise licensing, and research data partnerships operate on different sales cycles, customer profiles, and economic drivers.

Consumer

Direct-to-consumer longevity membership — quarterly biological age assessments, continuous monitoring, and personalized intervention protocols.

Revenue model

$4,800 annual membership ARR
Quarterly breath assessment sessions
Continuous wearable data integration
Personalized aging protocol updates
Longitudinal trajectory dashboard

Request access →View platform →

Enterprise

Multi-year platform licensing to health systems, insurers, and corporate wellness programs — white-labeled biological age assessment at scale.

Revenue model

$2.4M average annual contract value
Multi-year licensing agreements
Per-assessment volume pricing
White-label platform deployment
Dedicated clinical integration support

Discuss licensing →View science →

Research

Longitudinal biological aging data partnerships with pharmaceutical companies, biotech firms, and academic research institutions.

Revenue model

$12M per longitudinal cohort dataset
De-identified multi-year data access
Custom biomarker panel configuration
Clinical trial endpoint validation
Drug efficacy aging-signal tracking

Explore partnership →View science →

Go-to-market

Five acquisition channels.

Each channel targets a distinct buyer profile — from high-net-worth individuals seeking longevity optimization to CFOs evaluating population health ROI for self-insured employer programs.

Discuss partnership →

Direct-to-Consumer DigitalPerformance marketing · Longevity influencer · SEO
Concierge Medicine NetworksPhysician referral · Executive health programs · Clinics
Health System PartnershipsIDN procurement · Population health · Value-based care
Employer & Insurer ProgramsSelf-insured employers · Stop-loss carriers · Brokers
Pharmaceutical PartnershipsDrug development · Clinical trial endpoints · Biomarker data

Get in touch

For enterprise licensing, research partnerships, or investor inquiries — reach the EXHLS team directly.

Enterprise[email protected]

Health system and insurer licensing

Research[email protected]

Data partnerships and clinical collaboration

Investors[email protected]

Fundraising and investor relations

EXHLS is currently in Series A fundraising. Accredited investors and strategic partners may request a full financial model and investor deck.

Investor deck →